Integrating GLP-1 receptor agonists with anti-amyloid immunotherapy for Alzheimer's disease: a phased clinical roadmap

Junzhe Huang; Shengya Wang; Vincent C. T. Mok; Weihong Song; Ho Ko; Yun Zhang

doi:10.1093/lifemedi/lnaf036

Life Medicine ›› 2025, Vol. 4 ›› Issue (6) :lnaf036 DOI: 10.1093/lifemedi/lnaf036

News & Opinions

Integrating GLP-1 receptor agonists with anti-amyloid immunotherapy for Alzheimer's disease: a phased clinical roadmap

Junzhe Huang ¹^,²^,³^,⁴^,⁵
, Shengya Wang ⁶
, Vincent C. T. Mok ¹^,²^,³^,⁴^,⁵
, Weihong Song ⁶
, Ho Ko ¹^,²^,³^,⁴^,⁵
, Yun Zhang ⁷

Author information +

History +

PDF (1108KB)

Cite this article

Download citation ▾

Junzhe Huang, Shengya Wang, Vincent C. T. Mok, Weihong Song, Ho Ko, Yun Zhang. Integrating GLP-1 receptor agonists with anti-amyloid immunotherapy for Alzheimer's disease: a phased clinical roadmap. Life Medicine, 2025, 4(6): lnaf036 DOI:10.1093/lifemedi/lnaf036

登录浏览全文

4963

注册一个新账户忘记密码

References

Publishing order | Descend order by publishing year | Descend order by cited within

[1]	Loeffler DA . Antibody-mediated clearance of brain amyloid-β: mechanisms of action, effects of natural and monoclonal anti-Aβ antibodies, and downstream effects. J Alzheimers Dis Rep 2023; 7: 873- 99.

[2]	Zhang Y , Chen H , Feng Y et al. Activation of AMPK by GLP-1R agonists mitigates Alzheimer-related phenotypes in transgenic mice. Nat Aging 2025; 5: 1097- 113.

[3]	Huang J , Kwok AJ , Li JCY et al. Body-wide multi-omic counteraction of aging with GLP-1R agonism.Cell Metabolism 2025; 37: 2362- 80.e8.

[4]	Cummings JL , Atri A , Feldman HH et al. Evoke and evoke+: design of two large-scale, double-blind, placebo-controlled, phase 3 studies evaluating efficacy, safety, and tolerability of semaglutide in early-stage symptomatic Alzheimer's disease. Alzheimers Res Ther 2025; 17: 14.

[5]	van Olst L , Simonton B , Edwards AJ et al. Microglial mechanisms drive amyloid-β clearance in immunized patients with Alzheimer's disease. Nat Med 2025; 31: 1604- 16.